Omeprazole

What is Omeprazole?

Omeprazole is a proton pump inhibitor (PPI) that reduces stomach acid. Spanish Omeprazol Cinfamed product information covers reflux disease, peptic ulcers and use with appropriate antibiotics for H. pylori. Indications and prescription status depend on the exact product.

How does Omeprazole work?

Omeprazole is a prodrug that is activated in the acidic environment of the stomach’s parietal cells. Once activated, it covalently binds to and irreversibly inhibits the H⁺/K⁺-ATPase enzyme (the proton pump) — the final common pathway for acid secretion into the stomach lumen:

• Acid secretion blockade: By inhibiting the proton pump, Omeprazole reduces gastric acid secretion regardless of the stimulus (food, histamine, gastrin, or acetylcholine). This is more complete acid suppression than H2-receptor antagonists (e.g., famotidine).
• Healing of mucosal damage: Reduced gastric acidity allows the oesophageal and gastric mucosa to heal, which is particularly important in reflux oesophagitis and peptic ulceration.
• H. pylori eradication support: Omeprazole raises intragastric pH to a level at which antibiotic activity against H. pylori is enhanced, supporting the clinician-selected eradication regimen; antibiotic choice must account for resistance.
• Accumulation over days: Because Omeprazole inhibits only active pumps, and new pumps are continuously synthesised, maximum acid suppression builds up over the first 3–5 days of daily dosing rather than occurring after the first dose.

Who is Omeprazole for?

Omeprazole is indicated for:

• Gastro-oesophageal reflux disease (GERD): Including reflux oesophagitis, symptomatic GERD without oesophagitis, and maintenance to prevent relapse.
• Peptic ulcer disease: Treatment of gastric ulcers and duodenal ulcers, including prevention of NSAID-associated ulcers in high-risk patients.
• Helicobacter pylori eradication: With appropriate antibiotics selected using current guidance and resistance patterns. The product label and current empirical-treatment guidance are not interchangeable.
• Zollinger-Ellison syndrome: A rare condition of pathological gastric acid hypersecretion requiring high-dose PPI therapy.
• Heartburn: Assessment and instructions depend on the authorised product; this article does not establish a general non-prescription regimen.

Omeprazole is not appropriate as a substitute for investigation when:

• Symptoms could indicate serious upper GI pathology (dysphagia, unexplained weight loss, persistent vomiting, bleeding)
• Alarm symptoms are present — these warrant urgent gastroenterological assessment

Dosage

Examples from the Spanish Omeprazol Cinfamed label for adults follow. The prescriber selects the dose and suitable capsule strength; this is not a self-treatment table:

The label still lists 7-day triple regimens, but requires antibiotic selection according to resistance and treatment guidance. The V Spanish Consensus abstract recommends empirical quadruple approaches, generally 14 days. This distinction does not authorise changing an individual prescription; the clinician must select the complete regimen.

For Cinfamed capsules, take in the morning and swallow whole with water. If swallowing is difficult, the label permits opening the capsule and mixing the pellets with a suitable slightly acidic liquid or non-carbonated water. Take immediately or within 30 minutes, stir before drinking and rinse the glass with water. Do not chew or crush the gastro-resistant pellets.

Side effects

Adverse effects vary in frequency and severity.

Common side effects (may affect up to 1 in 10 people)

• Headache
• Abdominal pain
• Diarrhoea
• Nausea
• Flatulence
• Constipation

Other important risks

• Hypomagnesaemia: Low serum magnesium, particularly with long-term use (at least 3 months). Can cause muscle cramps, fatigue, tetany, and cardiac arrhythmias. Magnesium levels should be checked in patients on long-term PPI therapy.
• Vitamin B12 deficiency: Reduced gastric acid impairs B12 absorption from food. Risk increases with long-term use.
• Clostridium difficile (C. diff) colitis: Gastric acid provides a barrier to intestinal infection; PPI use is associated with a modestly increased risk of C. difficile colitis, particularly in hospital settings.
• Bone fractures: Long-term high-dose use has been associated with a modestly increased risk of osteoporotic fractures, possibly due to reduced calcium absorption.
• Interstitial nephritis: Rare but serious kidney inflammation associated with PPI use; often presents with non-specific symptoms.
• Subacute cutaneous lupus erythematosus (SCLE): Reported with proton pump inhibitors; seek assessment for a new rash, especially with joint pain.

Omeprazole vs alternatives

A clinician selects among them according to indication, response and interactions. This table does not rank omeprazole as having the highest suppression or establish equivalent doses or access.

Online assessment for Omeprazole

Prescrivia is a technology intermediary connecting patients with independent doctors and licensed pharmacies. We do not provide medical services, prescribe, employ doctors, sell or dispense medicines.

1. Assessment: Provide your symptoms or travel plans, medical history and all current medicines.
2. Independent review: A doctor decides whether a prescription is clinically appropriate; Prescrivia does not guarantee a prescription.
3. Dispensing: Any lawful dispensing is the responsibility of a licensed pharmacy, subject to the applicable rules and product availability.

In Spain, distance selling of prescription medicines is prohibited. An online assessment or a product label does not establish that a medicine can legally be supplied or delivered through this platform. This information does not change eligibility or fulfilment rules.

Important safety information

Do not take omeprazole if you have: hypersensitivity to omeprazole, substituted benzimidazoles or excipients, or if you take nelfinavir.

Seek urgent medical attention if you experience:

• Difficulty swallowing or pain when swallowing
• Unintentional weight loss
• Vomiting blood or material that looks like coffee grounds
• Black, tarry stools
• Persistent severe abdominal pain

These may be signs of serious upper gastrointestinal disease that requires investigation beyond PPI treatment.

Tell your doctor before starting Omeprazole if you have:

• Liver disease (Omeprazole is extensively metabolised by the liver)
• Kidney disease
• Osteoporosis or at risk of bone fractures
• A history of hypomagnesaemia
• Lupus

Drug interactions: Nelfinavir coadministration is contraindicated. Atazanavir coadministration is not recommended; concomitant clopidogrel should be avoided as a precaution. Omeprazole may affect diazepam, phenytoin, warfarin, digoxin, tacrolimus and methotrexate, and reduce absorption of itraconazole, posaconazole or erlotinib; the latter two combinations should be avoided. Disclose all medicines. The prescriber may need drug-level, kidney-function or magnesium monitoring.

Sources

• AEMPS: Omeprazol Cinfamed 20 mg, product information
• V Spanish Consensus on H. pylori treatment, original publication abstract
• BOE: Real Decreto Legislativo 1/2015, article 3.5

General information, not medical advice or a complete eradication protocol. A qualified clinician must apply current local guidance to the individual case.